BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Toripalimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Toripalimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06462222-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT06462222)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: Immune Checkpoint Inhibitor Co
 mbined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis
  From Solid Tumors\nEstimated primary completion: November 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06462222
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577532-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 1 readout est. (NCT06577532)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: Study of KRAS Neoantigen mRNA Va
 ccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06577532
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06525428-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06525428)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Standard Systemic Therapy Combin
 ed With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorec
 tal Cancer\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06525428
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06654947-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06654947)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Single-arm\, Open-label\, Pros
 pective Clinical Study of Surufatinib Combined With Immunotherapy and Chem
 otherapy for Unresectable or Metastatic Biliary Tract Cancer.\nEstimated p
 rimary completion: December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06654947
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06416696-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06416696)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab for High-risk Locall
 y Advanced Cervical Cancer\nEstimated primary completion: December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06416696
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06323239-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06323239)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: SBRT 
 and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngea
 l Carcinoma\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06323239
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914440-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06914440)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Neoadjuvant SBRT Followed by Nab
 -Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer\nEstimate
 d primary completion: December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06914440
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05340491-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05340491)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Chemo
 radiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter\, Open-label\, 
 Randomised\, Controlled\, Phase III Trial\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripal
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05340491
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06426511-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06426511)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: ctD
 NA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC\nEstimated 
 primary completion: 1 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06426511
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06571422-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Toripalimab: Phase 1 readout est. (NCT06571422)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: Phase I Study of WJ47156 Monothe
 rarpy and in Combination With Other Therapy in Advanced Solid Tumors\nEsti
 mated primary completion: 15 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06571422
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06088004-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT06088004)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: Phase Ⅰ/Ⅱ Clinical Study t
 o Evaluate ABO2011 in Advanced Solid Tumors\nEstimated primary completion:
  30 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/to
 ripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06088004
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768464-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Toripalimab: Phase 2 readout est. (NCT05768464)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Postoperative Adjuvant Therapy f
 or Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05768464
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06354231-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06354231)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: DV Combined With Toripalimab for
  Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral
  Multiple UTUC\nEstimated primary completion: 30 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06354231
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04772287-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04772287)
DESCRIPTION:Toripalimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Adj
 uvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage I
 I-IIIB(N2) NSCLC (LungMate-008)\nEstimated primary completion: 30 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT047722
 87
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06079112-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT06079112)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: 9MW2821 Combined With Toripali
 mab Injection in Subjects With Local Advanced or Metastatic Urothelial Can
 cer\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06079112
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06187597-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06187597)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Consolidation of Toripalimab Aft
 er Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06187597
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717464-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06717464)
DESCRIPTION:Toripalimab\, phase 2\, Cholangiocarcinoma.\nStudy: Toripalimab
  Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients
  With Resectable Advanced Extrahepatic Biliary Tract Cancer\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06717464
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05033392-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT05033392)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: PD-1 Blockade With JS001 Plus Ne
 oadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05033392
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05798845-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT05798845)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The
  Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage I
 I-IIIA (N+) Non Small Cell Lung Cancer\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripal
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05798845
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05975307-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT05975307)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Treating Muscle-invasive Bladder
  Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Che
 moradiation\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05975307
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04918186-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT04918186)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Immunotherapy Platform Study in 
 Platinum Resistant High Grade Serous Ovarian Cancer\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04918186
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03859128-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2/3 readout est. (NCT03859128)
DESCRIPTION:Toripalimab\, phase 2/3.\nStudy: Toripalimab or Placebo as Adju
 vant Therapy in Hepatocellular Carcinoma After Radical Resection\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03859128
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05302284-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05302284)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: A Study of RC48-ADC Combined Wit
 h Toripalimab For First-line Treatment of Urothelial Carcinoma\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05302284
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04523493-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04523493)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Phase III Study of Toripalimab
 （JS001） Combined With Lenvatinib for Advanced HCC\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04523493
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06791070-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06791070)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Study of RC48-ADC Combined Wit
 h JS001 for Advanced Extramammary Paget Disease of the Scrotum\nEstimated 
 primary completion: January 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06791070
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493980-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07493980)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resecta
 ble Stage II-III Non-small Cell Lung Cancer Patients\nEstimated primary co
 mpletion: January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07493980
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882876-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Toripalimab: Phase 1 readout est. (NCT06882876)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: JS014 Combined With Toripalimab 
 and TACE in Unresectable HCC: a Phase Ib Study\nEstimated primary completi
 on: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 oripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06882876
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904573-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06904573)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Probiotics in Advanced Urothelia
 l Carcinoma\nEstimated primary completion: 1 January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06904573
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615974-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT05615974)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: A Phase I/II Study of LM-101 I
 njection in Patients With Advanced Malignant Tumors\nEstimated primary com
 pletion: 11 January 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05615974
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589741-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Toripalimab: Phase 2 readout est. (NCT04589741)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab Combined With CAV/IE
  Regimen\nEstimated primary completion: 30 January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04589741
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06256237-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06256237)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Neoadjuvant Therapy With Toripal
 imab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limit
 ed-stage Small Cell Lung Cancer : A Phase 2 Trial\nEstimated primary compl
 etion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06256237
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06269211-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06269211)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cel
 l Lung Cancer with EGFR Mutation and PD-L1 Positive Expression\nEstimated 
 primary completion: 31 January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06269211
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06208410-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT06208410)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: A Clinical Study of JS105 in C
 ombination With Other Anti-tumor Therapies in Patients With Solid Tumors\n
 Estimated primary completion: 26 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06208410
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07835035-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07835035)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: Rimegepant Plus Toripalimab in A
 dvanced Urothelial Carcinoma After Failure of Standard Therapy\nEstimated 
 primary completion: 28 February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07835035
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06889649-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06889649)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: SABR Combined with Axitinib and 
 Toripalimab in Recurrent or Metastatic RCC\nEstimated primary completion: 
 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tor
 ipalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06889649
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438600-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07438600)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Sta
 ge II-IIIB NSCLC\nEstimated primary completion: 28 February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07438600
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06623136-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06623136)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of ES102 in Combination With Toripalimab in Subjects With Advanced No
 n-small Cell Lung Cancer\nEstimated primary completion: 28 February 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06623136
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06977893-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06977893)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Neoadjuvant Chemotherapy in Comb
 ination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized\, Open
 -label\, Parallel-controlled\, Multi-center Phase III Study (NEOTORCH-BREA
 ST04)\nEstimated primary completion: 23 March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06977893
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07320963-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270328
DTEND;VALUE=DATE:20270329
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07320963)
DESCRIPTION:Toripalimab\, phase 1/2\, Nasopharyngeal Carcinoma.\nStudy: Chi
 damide in Combination With Toripalimab and Anlotinib in Recurrent/Metastat
 ic Nasopharyngeal Carcinoma.\nEstimated primary completion: 28 March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07320963
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04387084-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Toripalimab: Phase 1 readout est. (NCT04387084)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: Short-term Fasting Prior to PD-1
 /PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy\nEs
 timated primary completion: 31 March 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04387084
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180734-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05180734)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: PD1 Combined With Chemotherapy f
 or Adjuvant Treatment of Gastric Cancer\nEstimated primary completion: 31 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5180734
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647289-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07647289)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: EV + Toripalimab vs GC as Neoadj
 uvant Therapy in Locally Advanced/High-Risk MIBC\nEstimated primary comple
 tion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tor
 ipalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07647289
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03926338-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Toripalimab: Phase 2 readout est. (NCT03926338)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Neoadjuvant Toripalimab With or 
 Without Celecoxib in dMMR/MSI-H Colorectal Cancer\nEstimated primary compl
 etion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03926338
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06919848-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06919848)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Oncolytic Virus H101 Combined Wi
 th Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advan
 ced Biliary Tract Cancer (OPTIONS-06)\nEstimated primary completion: 1 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069198
 48
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848753-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04848753)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Perioperative Toripalimab (JS001
 ) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Local
 ly Advanced Thoracic Esophageal Squamous Cell Carcinoma\nEstimated primary
  completion: 12 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04848753
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07040228-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07040228)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: A Phase Ib/II Clinical Study o
 f Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for t
 he Third-line Treatment of Advanced Pancreatic Cancer\nEstimated primary c
 ompletion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07040228
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159217-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07159217)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Disitamab Vedotin Plus Lenvatini
 b and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Ca
 ncer\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07159217
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05342194-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05342194)
DESCRIPTION:Toripalimab\, phase 3\, Cholangiocarcinoma.\nStudy: Toripalimab
  Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Adv
 anced ICC: a Phase III Study\nEstimated primary completion: 31 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05342194
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06851247-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06851247)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: GAPP 
 Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Mainten
 ance for Nasopharyngeal Carcinoma.\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06851247
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07040644-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07040644)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Study of Sacituzumab Govitecan
  Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive
  Advanced TNBC\nEstimated primary completion: June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07040644
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727993-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07727993)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: Neoadjuvant Propranolol Plus S
 OX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07727993
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878625-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06878625)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Multicenter\, Prospective\, Co
 hort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative 
 Breast Cancer\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06878625
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484724-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07484724)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Study Evaluating the Safety an
 d Efficacy of JS212 Combination Therapy in Patients With Advanced Esophage
 al Squamous Cell Carcinoma\nEstimated primary completion: 30 June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07484724
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06235203-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06235203)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Neoad
 juvant vs Adjuvant in Locally Advanced Recurrent NPC\nEstimated primary co
 mpletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06235203
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106034-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07106034)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Standard Second-line Therapy Wit
 h ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm 
 Phase II Trial\nEstimated primary completion: 31 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07106034
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06095583-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06095583)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Phase 3 Study of Toripalimab Alo
 ne or in Combination With Tifcemalimab as Consolidation Therapy in Patient
 s With Limited-stage Small Cell Lung Cancer (LS-SCLC)\nEstimated primary c
 ompletion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06095583
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540533-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07540533)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Multicohort Study of Toripalim
 ab in Combination With Investigator-Selected Chemotherapy for Advanced HER
 2-Negative Breast Cancer\nEstimated primary completion: August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07540533
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868199-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT06868199)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: A Study of LM-168 as a Single 
 Agent or in Combination With Toripalimab in Subjects With Advanced Solid T
 umours\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06868199
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843889-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06843889)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Phase II Study of Toripalimab 
 Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Es
 ophageal Squamous Cell Carcinoma\nEstimated primary completion: 1 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06843889
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07088211-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07088211)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Sacituzumab Tirumotecan and Tori
 palimab in the First-line Treatment of HNSCC\nEstimated primary completion
 : 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tori
 palimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07088211
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720921-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07720921)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Neoadjuvant Disitamab Vedotin\, 
 Toripalimab\, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )\nEstimated
  primary completion: 1 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07720921
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151560-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07151560)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Efficacy and Safety of Two Bladd
 er-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab 
 Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II\
 , Open-Label\, Randomized Clinical Trial\nEstimated primary completion: 30
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripal
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07151560
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05484375-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Toripalimab: Phase 2 readout est. (NCT05484375)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Capec
 itabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal 
 Carcinoma After First-line Treatment\nEstimated primary completion: Septem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 84375
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679985-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06679985)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Trial of Casdozokitug in Combi
 nation With Toripalimab Plus Bevacizumab in Participants With Unresectable
  and/or Locally Advanced or Metastatic Hepatocellular Carcinoma\nEstimated
  primary completion: September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06679985
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06592326-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06592326)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: 9MW2821 in Combination With Tori
 palimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothel
 ial Cancer\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06592326
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783815-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07783815)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: A Study to Evaluate the Efficacy
  and Safety of Intravesical Instillation of Disitamab Vedotin Combined Wit
 h Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive
  Bladder Cancer Who Are BCG-Naïve or Have BCG Failure\nEstimated primary 
 completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07783815
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06208826-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06208826)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Single-center Phase II Study t
 o Investigate the Immune Maintenance Therapy Pattern in Patients With Loca
 lly Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR A
 fter Neoadjuvant Immunotherapy Combined With Chemotherapy\nEstimated prima
 ry completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06208826
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07189793-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07189793)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab ± Sequential Intrav
 esical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk 
 NMIBC: Open-Label Randomized Phase 2 Study\nEstimated primary completion: 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripal
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07189793
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04861584-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271003
DTEND;VALUE=DATE:20271004
SUMMARY:Toripalimab: Phase 2 readout est. (NCT04861584)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Neoadjuvant Toripalimab in Combi
 nation With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Ca
 ncer Subjects\nEstimated primary completion: 3 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04861584
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099430-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07099430)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: A Trial of LBL-024 Monotherapy
  or Combination With Toripalimab in Patients With Advanced Melanoma.\nEsti
 mated primary completion: 30 October 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07099430
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06378177-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06378177)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Study of LVGN6051 Combination 
 Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)\nEst
 imated primary completion: 31 October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06378177
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06283121-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06283121)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Clinical Study of BioTTT001 in
  Combination With SOX and Toripalimab in Patients With Gastric Cancer\nEst
 imated primary completion: 30 November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06283121
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101614-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07101614)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Randomized Study of JS004 and 
 Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemot
 herapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Tripl
 e-negative Breast Cancer (TNBC).\nEstimated primary completion: 30 Novembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07101
 614
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309276-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07309276)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Phase II Clinical Study Evalua
 ting the Combination Therapy of JS212 in Patients With Advanced Lung Cance
 r\nEstimated primary completion: 30 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07309276
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480733-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07480733)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Phase II Study of JS212/JS213 as
  Monotherapy and in Combination in Patients With Advanced Malignant Solid 
 Tumors\nEstimated primary completion: 30 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07480733
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05917158-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT05917158)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Study of RC48-ADC Combined wit
 h JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Car
 cinoma\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05917158
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07481058-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07481058)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: KC1036 in Combination With PD-1 
 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophagea
 l Cancer\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07481058
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06457503-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 4 readout est. (NCT06457503)
DESCRIPTION:Toripalimab\, phase 4.\nStudy: A Study of Toripalimab in Combin
 ation With Cisplatin and Gemcitabine in Participants With Recurrent Metast
 atic Nasopharyngeal Cancer\nEstimated primary completion: December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06457503
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06283134-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Toripalimab: Phase 1 readout est. (NCT06283134)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: A Clinical Study of BioTTT001 in
  Combination With Toripalimab and Regorafenib in Patients With Colorectal 
 Cancer\nEstimated primary completion: 1 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06283134
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307456-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07307456)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab Combined With BCG Pe
 rfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration\nEst
 imated primary completion: 8 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07307456
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07279597-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07279597)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Phase II Study of Toripalimab 
 Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive 
 Muscle-Invasive Bladder Cancer\nEstimated primary completion: 10 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0727959
 7
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246330-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07246330)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Stratified Treatment in Unresect
 able Locally Advanced ESCC Without Progression After Chemoimmunotherapy In
 duction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective
 \, Randomized\, Controlled Phase III Multicenter Study\nEstimated primary 
 completion: 15 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07246330
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286942-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271218
DTEND;VALUE=DATE:20271219
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07286942)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ste
 reotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (
 QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable 
 Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm\, Singl
 e-centre\, Phase 2 Trial\nEstimated primary completion: 18 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07286942
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05869227-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05869227)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Maint
 enance Therapy With Toripalimab Combined With Capecitabine/Placebo for Rec
 urrent and Metastatic Nasopharyngeal Carcinoma\nEstimated primary completi
 on: 20 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05869227
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07272291-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07272291)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Phase II Study of Toripalimab 
 Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refrac
 tory Esophageal Squamous Cell Carcinoma\nEstimated primary completion: 25 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripa
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07272291
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952621-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06952621)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Neoadjuvant Treatment of Toripal
 imab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxe
 l Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous 
 Cell Carcinoma\nEstimated primary completion: 28 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06952621
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975293-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271229
DTEND;VALUE=DATE:20271230
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT06975293)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: STC-15 as a Part of Combinatio
 n Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy
  in Participants With Selected Sarcomas\nEstimated primary completion: 29 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripa
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06975293
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07201675-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07201675)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Vedisertib (RC48/ADC) Combined W
 ith Toripalimab in Bladder-preserving Treatment\nEstimated primary complet
 ion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07201675
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07380633-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07380633)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab Plus Bevacizumab Com
 bined Three Intra-arterial Therapies (TACE\, HAIC\, or TACE-HAIC) for Unre
 sectable Hepatocellular Carcinoma: a Phase 2\, Multicenter Randomised Non-
 comparative Trial\nEstimated primary completion: 30 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07380633
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744932-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07744932)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: SABR Combined With Axitinib and 
 Toripalimab for Oligometastatic Renal Cell Carcinoma\nEstimated primary co
 mpletion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07744932
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816770-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07816770)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: MANTIS-RCC: Toripalimab-Axitinib
  Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Car
 cinomas\nEstimated primary completion: 30 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07816770
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07004244-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07004244)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: Application of KRAS Vaccine in t
 he Treatment of KRAS-mutated Malignancies\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tori
 palimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07004244
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05502393-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 1 readout est. (NCT05502393)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: A Clinical Study to Evaluate the
  Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05502393
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Study of Precision Treatment for
  Rare Tumours in China Guided by PDO and NGS\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 oripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06692491
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314723-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07314723)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: 9MW2821 Combined With Toripalima
 b in Perioperative Patients With Urothelial Cancer\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07314723
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363330-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07363330)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Phase II Study of Utidelone Wi
 th Toripalimab in Advanced Cervical Cancer\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tor
 ipalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07363330
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555860-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07555860)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Becot
 atug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectab
 le Locally Recurrent Nasopharyngeal Carcinoma\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07555860
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571551-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07571551)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Perioperative Trial With IO/TKI 
 for Multi-stage Clear Cell Renal Cell Carcinoma\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07571551
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06964906-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06964906)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Neoadjuvant High-Intensity Focus
 ed Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Pos
 itive /HER2-Negative Breast Cancer\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 64906
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776717-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07776717)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: TACTIC-RCC: Toripalimab Plus Axi
 tinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-P
 ositive Advanced Clear Cell Renal Cell Carcinoma\nEstimated primary comple
 tion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07776717
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897565-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07897565)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Safety and Efficacy of Gemcitabi
 ne\, Toripalimab and Dose- Modified Lenvatinib in Elderly Patients With Ad
 vanced Biliary Tract Cancer Intolerant to Conventional Chemotherapy\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07897565
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214987-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07214987)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: PDT For Induction Therapy For He
 ad And Neck Cancer\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07214987
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876557-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07876557)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Clinical Study to Evaluate the
  Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurr
 ent or Metastatic Triple-negative Breast Cancer(TNBC)\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07876557
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Toripalimab\, phase 2/3.\nStudy: Precision Medicine for Immunot
 herapy-Resistant Advanced Esophageal Cancer\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/to
 ripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07653451
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05738694-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05738694)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Neoadjuvant of Axitinib Plus PD-
 1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05738694
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07928362-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase na readout est. (NCT07928362)
DESCRIPTION:Toripalimab\, phase na.\nStudy: A Multicenter\, Prospective Sin
 gle-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and 
 AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer\nEstimated 
 primary completion: 31 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07928362
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06657144-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Toripalimab: Phase 1 readout est. (NCT06657144)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: A Study of CHS-114 (Tagmokitug) 
 in Combination With Toripalimab and/or Other Treatments in Participants Wi
 th Advanced Solid Tumors\nEstimated primary completion: January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06657144
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: Safety and Efficacy of HCB101 
 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
 \nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358689-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07358689)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tor
 ipalimab Combined With Platinum-based Chemotherapy With or Without H1 Rece
 ptor Antagonist in the Perioperative Treatment of Resectable Non-small Cel
 l Lung Cancer\nEstimated primary completion: 1 January 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07358689
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669220-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07669220)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Multicenter\, Randomized Contr
 olled Phase II Study of Short-Course Radiotherapy Followed by Sequential P
 D-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy
  for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR
  Trial)\nEstimated primary completion: 1 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07669220
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07457359-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280104
DTEND;VALUE=DATE:20280105
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07457359)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Neoadjuvant Toripalimab Plus SBR
 T for Chemo-Resistant Triple-Negative Breast Cancer\nEstimated primary com
 pletion: 4 January 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07457359
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03810339-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Toripalimab: Phase 2 readout est. (NCT03810339)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab（JS001） as Monoth
 erapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced S
 olid Tumors\nEstimated primary completion: 15 January 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03810339
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06873854-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280126
DTEND;VALUE=DATE:20280127
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06873854)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Study of LM-108 in Combination
  With Toripalimab in Subjects With Advanced Solid Tumours\nEstimated prima
 ry completion: 26 January 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06873854
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244874-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07244874)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Sac-TMT Combined With Toripalima
 b for First-line Treatment of PD-L1 Positive a/mTNBC\nEstimated primary co
 mpletion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07244874
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325539-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07325539)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: LDRT Combined With Toripalimab a
 nd Chemotherapy for Recurrent/Metastatic NPC\nEstimated primary completion
 : 30 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/to
 ripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07325539
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469956-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07469956)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Surufatinib Plus mFOLFIRINOX and
  PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Res
 ectable Pancreatic Cancer\nEstimated primary completion: 31 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07469956
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258979-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07258979)
DESCRIPTION:Toripalimab\, phase 1/2\, Nasopharyngeal Carcinoma.\nStudy: A S
 tudy of YL201 in Combination With Toripalimab and With or Without Cisplati
 n in Nasopharyngeal Carcinoma.\nEstimated primary completion: February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07258979
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383818-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07383818)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Neoadjuvant Therapy Combined Wit
 h Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NE
 OTORCH-BREAST 08)\nEstimated primary completion: 1 February 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07383818
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940180-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06940180)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab With Chemotherapy fo
 r Sinus Cancer\nEstimated primary completion: 1 February 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06940180
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832982-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280219
DTEND;VALUE=DATE:20280220
SUMMARY:Toripalimab: Phase 1 readout est. (NCT06832982)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: Evaluating the Safety\, Tolerabi
 lity\, Pharmacokinetics\, Pharmacokinetics\, and Preliminary Efficacy of F
 S-8002\nEstimated primary completion: 19 February 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06832982
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410234-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280221
DTEND;VALUE=DATE:20280222
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07410234)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Phase II Exploratory Study of To
 ripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With 
 Insensitivity to Neoadjuvant Chemotherapy\nEstimated primary completion: 2
 1 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tori
 palimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07410234
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630363-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07630363)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: PTC-Guided Atorvastatin Plus A
 xitinib and Toripalimab in Advanced RCC\nEstimated primary completion: 1 M
 arch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 630363
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388836-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07388836)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Timin
 g Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locall
 y Advanced Nasopharyngeal Carcinoma\nEstimated primary completion: 1 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073888
 36
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07879469-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07879469)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Antibody-Drug Conjugate Plus Imm
 unotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transureth
 rally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer\nEsti
 mated primary completion: 1 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07879469
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625423-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07625423)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: Intratumoral Injection of Recomb
 inant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent o
 r Metastatic Head and Neck Tumors\nEstimated primary completion: 30 March 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0762542
 3
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07500831-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Toripalimab: Phase na readout est. (NCT07500831)
DESCRIPTION:Toripalimab\, phase na.\nStudy: Fasting-Mimicking Diet Combined
  With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Ca
 rcinoma\nEstimated primary completion: April 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07500831
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06903858-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06903858)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab Plus Celecoxib for d
 MMR/MSI-H Locally Advanced Colorectal Cancer\nEstimated primary completion
 : 1 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/torip
 alimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06903858
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550842-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07550842)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: A Clinical Study for the Safety 
 and Efficacy of BL0020 Injection in Combination With Toripalimab Injection
  in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer\nEstima
 ted primary completion: 28 April 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07550842
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562841-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07562841)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: Au-TMP and Radiotherapy for Adva
 nced Melanoma With Anti-PD-1 Therapy\nEstimated primary completion: 30 Apr
 il 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0756
 2841
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06341400-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT06341400)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: RC48 Combined With Toripalimab
  as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients\nEstimated 
 primary completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06341400
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796126-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280529
DTEND;VALUE=DATE:20280530
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07796126)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Sequential Toripalimab and Pacli
 taxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor
  Performance Status\nEstimated primary completion: 29 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07796126
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389526-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Toripalimab: Phase 1 readout est. (NCT06389526)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: A Study of CHS-1000 in Participa
 nts With Advanced or Metastatic Solid Tumors\nEstimated primary completion
 : 30 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripa
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06389526
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177794-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07177794)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Consolidation of Toripalimab and
  Capecitabine After Chemoradiotherapy in ESCC\nEstimated primary completio
 n: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/torip
 alimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07177794
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559929-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07559929)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: A Study of DXC006 With Immune 
 Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.\nEstimated p
 rimary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07559929
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680582-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07680582)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: An Exploratory Study of Personal
 ized Cancer Vaccine in Adjuvant Therapy of Solid Tumors\nEstimated primary
  completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07680582
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685535-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07685535)
DESCRIPTION:Toripalimab\, phase 2\, Cholangiocarcinoma.\nStudy: HAIC + DEB-
 TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocar
 cinoma\nEstimated primary completion: 30 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07685535
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717242-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07717242)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Sun Yat-Sen Treatment Strategy f
 or Enhancing Response in Muscle-invasive Bladder Cancer\nEstimated primary
  completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07717242
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228079-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06228079)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Adjuv
 ant vs Surgery Only in Early-stage Recurrent NPC\nEstimated primary comple
 tion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 oripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06228079
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07445295-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07445295)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Chiauranib Plus PD-1 Inhibitor\,
  Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic
  Ductal Adenocarcinoma\nEstimated primary completion: 30 June 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07445295
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896681-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07896681)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab Plus Cetuximab and I
 rinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Ca
 ncer Phase II Study\nEstimated primary completion: 1 July 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07896681
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619235-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Toripalimab: Phase 4 readout est. (NCT07619235)
DESCRIPTION:Toripalimab\, phase 4.\nStudy: A Single-arm\, Multicenter Clini
 cal Study of Iparomlimab and Toripalimab in Combination With Bevacizumab a
 nd Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer\
 nEstimated primary completion: 1 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07619235
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855965-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280805
DTEND;VALUE=DATE:20280806
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07855965)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Mul
 ticenter\, Single-Arm\, Prospective Phase II Study of Neoadjuvant Cryo-The
 rmal Ablation Combined With Toripalimab and Chemotherapy for Resectable St
 age IB-IIIB Non-Small Cell Lung Cancer\nEstimated primary completion: 5 Au
 gust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 855965
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362186-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07362186)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: LM-108 in Combination With Torip
 alimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8
 -Positive Gastric and Gastroesophageal Junction Adenocarcinoma\nEstimated 
 primary completion: 17 August 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07362186
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561763-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280820
DTEND;VALUE=DATE:20280821
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06561763)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: TPC V
 S. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in th
 e Treatment of Locally Advanced Nasopharyngeal Carcinoma\nEstimated primar
 y completion: 20 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06561763
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778368-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07778368)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Multicenter\, Prospective\, Ph
 ase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable 
 Locally Advanced Oral Squamous Cell Carcinoma\nEstimated primary completio
 n: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/to
 ripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07778368
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07906587-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07906587)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Locally Advanced Resectable Head
  and Neck Squamous Cell Carcinoma: A Prospective\, Single-Arm Clinical Stu
 dy\nEstimated primary completion: October 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07906587
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808216-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07808216)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab Combined With Intrav
 esical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive B
 ladder Cancer After TURBT\nEstimated primary completion: 1 October 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07808216
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712888-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281126
DTEND;VALUE=DATE:20281127
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06712888)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Torip
 alimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanc
 ed Nasopharyngeal Carcinoma\nEstimated primary completion: 26 November 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06712888
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06719700-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281129
DTEND;VALUE=DATE:20281130
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06719700)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Concurrent Chemoradiotherapy Com
 bined With Toripalimab and Surufatinib in the Treatment of Limited-Stage S
 mall Cell Lung Cancer\nEstimated primary completion: 29 November 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06719700
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706219-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06706219)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Eff
 icacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With T
 oripalimab in Patients With Initially Unresectable Stage III NSCLC\nEstima
 ted primary completion: 30 November 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06706219
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412171-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07412171)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: NECTAR Study: Neoadjuvant Toripa
 limab + 9MW2821 for Local UTUC\nEstimated primary completion: December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07412171
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823270-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07823270)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Neoadjuvant Sacituzumab Tirumote
 can Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinom
 a\nEstimated primary completion: December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07823270
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819578-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07819578)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tor
 ipalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectabl
 e NSCLC\nEstimated primary completion: 1 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07819578
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245901-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281205
DTEND;VALUE=DATE:20281206
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07245901)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: Safety and Tolerability of a m
 RNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination W
 ith Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors\n
 Estimated primary completion: 5 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07245901
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281716-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07281716)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: Combination Immunotherapy for 
 the Treatment of Chemotherapy-refractory Metastatic MSS CRC\nEstimated pri
 mary completion: 15 December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07281716
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06682780-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281225
DTEND;VALUE=DATE:20281226
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT06682780)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: A Phase I/II Study of LM-2417 
 in Subjects With Advanced Solid Tumours\nEstimated primary completion: 25 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripa
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06682780
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07508761-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07508761)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: IPG7236 Combined With Toripali
 mab in Participants With Advanced Solid Tumors\nEstimated primary completi
 on: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07508761
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06965231-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06965231)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Perioperative Toripalimab and En
 dostatin for Stage II Melanoma: A Phase II Trial\nEstimated primary comple
 tion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06965231
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07039656-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07039656)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tor
 ipalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell
  Lung Cancer With or Without Prior Neoadjuvant Therapy\nEstimated primary 
 completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07039656
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683832-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07683832)
DESCRIPTION:Toripalimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety\, Tolerability\, Immunogenicity\, Pharmacodynamic Characteristics\, an
 d Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone an
 d in Combination With Toripalimab in Participants With Resected NSCLC\nEst
 imated primary completion: 31 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07683832
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07886229-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07886229)
DESCRIPTION:Toripalimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Pro
 pranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemot
 herapy in Resectable Non-Small Cell Lung Cancer\nEstimated primary complet
 ion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07886229
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277322-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07277322)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: Neoadjuvant Dupilumab and Tori
 palimab in MSS CRC Subjects With Resectable Liver Metastases\nEstimated pr
 imary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07277322
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06751394-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06751394)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Preoperative Chemoradiotherapy a
 nd Toripalimab in Locally Recurrent Rectal Cancer\nEstimated primary compl
 etion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06751394
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07256964-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07256964)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab Combined With Anthra
 cycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemo
 therapy for Early Triple Negative Breast Cancer\nEstimated primary complet
 ion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07256964
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05441475-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT05441475)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Phase 2\, Open-Label Study of 
 ABSK-011 Combined Atezolizumab or SOC in HCC Patients\nEstimated primary c
 ompletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05441475
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646080-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07646080)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Exploratory Study on Toripalimab
  and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatof
 ibrosarcoma Protuberans\nEstimated primary completion: 31 December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07646080
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07611825-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07611825)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Gut Microbiota Modulation for Im
 munotherapy Resensitization in Advanced Renal Cell Carcinoma\nEstimated pr
 imary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07611825
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935759-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 2/3 readout est. (NCT07935759)
DESCRIPTION:Toripalimab\, phase 2/3.\nStudy: Efficacy and Safety Exploratio
 n of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in 
 Neoadjuvant Treatment of Locally Advanced Rectal Cancer\nEstimated primary
  completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07935759
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04365036-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04365036)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: A Multicenter\, Phase 3\, Random
 ized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD
 -1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Ce
 ll Lymphoma\, Nasal Type (ENKTL)\nEstimated primary completion: 31 Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04365
 036
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06256224-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Toripalimab: Phase na readout est. (NCT06256224)
DESCRIPTION:Toripalimab\, phase na.\nStudy: Toripalimab Combined With Defin
 itive CCRT for LACC Patients\nEstimated primary completion: 31 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06256224
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06592599-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06592599)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Gemci
 tabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Ass
 ociated Nasopharyngeal Carcinoma(NPC)\nEstimated primary completion: Janua
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0659
 2599
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817095-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07817095)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: SBRT Combined With Reduced-Dose 
 Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Loca
 lized High-Risk Undifferentiated Pleomorphic Sarcoma\nEstimated primary co
 mpletion: January 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07817095
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06709274-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Toripalimab: Phase na readout est. (NCT06709274)
DESCRIPTION:Toripalimab\, phase na\, Non-Small Cell Lung Cancer.\nStudy: Mi
 nimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC\nEstimate
 d primary completion: January 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06709274
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07907861-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07907861)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Sacituzumab Tirumotecan Plus Tor
 ipalimab for Advanced Penile Cancer After Platinum Chemotherapy\nEstimated
  primary completion: 1 January 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07907861
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677475-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290130
DTEND;VALUE=DATE:20290131
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07677475)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: MRG003 Plus Toripalimab Versus T
 oripalimab as Neoadjuvant Therapy for PD-L1-Positive\, Resectable\, Locall
 y Advanced Head and Neck Squamous Cell Carcinoma\nEstimated primary comple
 tion: 30 January 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07677475
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583953-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07583953)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: An Exploratory Study of Personal
 ized Cancer Vaccine in Adjuvant Therapy of Solid Tumors\nEstimated primary
  completion: 31 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07583953
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07584135-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07584135)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: JS107 in Combination With Toripa
 limab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or G
 astroesophageal Junction Adenocarcinoma\nEstimated primary completion: 31 
 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripal
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07584135
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06903871-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06903871)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab Adjuvant Therapy in 
 Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pat
 hological Complete Response (pCR)\nEstimated primary completion: 1 March 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06903871
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362979-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290312
DTEND;VALUE=DATE:20290313
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07362979)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Torip
 alimab Combined With Different Platinum-Based Induction Chemotherapy Regim
 ens for Locally Advanced Nasopharyngeal Carcinoma\nEstimated primary compl
 etion: 12 March 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07362979
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06912711-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290420
DTEND;VALUE=DATE:20290421
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06912711)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: TN In
 duction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal
  Carcinoma\nEstimated primary completion: 20 April 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06912711
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423078-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07423078)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Window of Opportunity in Preserv
 ing Laryngeal Function Trial\nEstimated primary completion: 30 April 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07423078
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608159-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07608159)
DESCRIPTION:Toripalimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-
 III NSCLC.\nEstimated primary completion: May 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07608159
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987123-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06987123)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: TC as
  Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasophary
 ngeal Carcinoma: a Single-arm Clinical Trial\nEstimated primary completion
 : 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripa
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06987123
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953323-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT06953323)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: A Phase I/II Study of WJB001 C
 ombination Therapy on Safety and Efficacy for Advanced Solid Tumors\nEstim
 ated primary completion: 30 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06953323
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047001-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07047001)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Vorolanib Monotherapy or in Comb
 ination With Toripalimab as Adjuvant Therapy for Patients With Intermediat
 e-high Risk of Recurrence in Renal Cell Carcinoma\nEstimated primary compl
 etion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07047001
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07378306-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07378306)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: FMD and Neoadjuvant Chemo-immuno
 therapy in TNBC\nEstimated primary completion: 30 June 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07378306
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140679-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07140679)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Immunotherapy (Toripalimab) for 
 Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage
  IIB\, IIC\, or III Colon Cancer\nEstimated primary completion: 31 July 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07140679
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110558-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290814
DTEND;VALUE=DATE:20290815
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07110558)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Radio
 therapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuva
 nt Toripalimab in Nasopharyngeal Carcinoma\nEstimated primary completion: 
 14 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/torip
 alimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07110558
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06636981-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06636981)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: All Trans Retinoic Acid Combined
  with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastat
 ic Triple Negative Breast Cancer：a Multi-center\, Multi-cohort Phase II 
 Trial\nEstimated primary completion: September 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06636981
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647563-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06647563)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Neoadjuvant Toripalimab + Chemot
 herapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcin
 oma (Neo-ICT)\nEstimated primary completion: 30 September 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06647563
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392060-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07392060)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: A Phase III Clinical Study of WX
 390 Combined With Toripalimab Versus Investigator's Choice of Therapy in P
 atients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior
  Platinum-Based Treatment\nEstimated primary completion: 30 September 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07392060
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07332221-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07332221)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Application of Toripalimab as Ad
 juvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Tri
 al\nEstimated primary completion: 1 October 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07332221
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392736-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20291107
DTEND;VALUE=DATE:20291108
SUMMARY:Toripalimab: Phase 1/2 readout est. (NCT07392736)
DESCRIPTION:Toripalimab\, phase 1/2.\nStudy: A Phase I/IIa Study of AL8326 
 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.\nEsti
 mated primary completion: 7 November 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07392736
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07853053-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07853053)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: DV Plus Toripalimab With Cetiriz
 ine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresec
 table or Metastatic Bladder Cancer\nEstimated primary completion: 31 Decem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 53053
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136519-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07136519)
DESCRIPTION:Toripalimab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Torip
 alimab\, Induction Chemotherapy\, Radiation Therapy With Omega-3 for Local
 ly Advanced Nasopharyngeal Carcinoma\nEstimated primary completion: 31 Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7136519
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505472-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Toripalimab: Phase 2/3 readout est. (NCT07505472)
DESCRIPTION:Toripalimab\, phase 2/3.\nStudy: Efficacy and Safety Comparison
  of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripal
 imab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid
 -to-low Localized Rectal Cancer of High-risk Criteria\nEstimated primary c
 ompletion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07505472
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07698054-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07698054)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab Combined With Beat C
 hemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer\
 nEstimated primary completion: 1 January 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07698054
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07290621-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07290621)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab in Combination With 
 Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer\n
 Estimated primary completion: February 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07290621
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06277050-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20300220
DTEND;VALUE=DATE:20300221
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06277050)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Maint
 enance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone
  in High-risk Nasopharyngeal Carcinoma\nEstimated primary completion: 20 F
 ebruary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripal
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06277050
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608224-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Toripalimab: Phase 2/3 readout est. (NCT07608224)
DESCRIPTION:Toripalimab\, phase 2/3.\nStudy: HOPE-07-MIBC: Disitamab Vedoti
 n Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing M
 IBC\nEstimated primary completion: 30 June 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07608224
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07097948-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07097948)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Toripalimab Combined With Chemot
 herapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Rad
 ical Resection of Lung Cancer: A Single-Center\, Randomized Controlled Cli
 nical Study Protocol Number: LungMate-033\nEstimated primary completion: J
 uly 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 97948
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209189-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20301001
DTEND;VALUE=DATE:20301002
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07209189)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Neoadjuvant Chemotherapy and Pro
 grammed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Tre
 atment De-escalation (NeoScorch HN)\nEstimated primary completion: 1 Octob
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0720
 9189
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898124-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Toripalimab: Phase 1 readout est. (NCT07898124)
DESCRIPTION:Toripalimab\, phase 1.\nStudy: TMV Vaccine Alone or With Toripa
 limab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma\nEstimated 
 primary completion: 31 December 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07898124
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836049-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07836049)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: PhII Study of Toripalimab Follow
 ed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC\nEsti
 mated primary completion: 31 December 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07836049
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474064-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07474064)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Probiotics Combined With Targete
 d Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients Wi
 th MIBC\nEstimated primary completion: 31 March 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07474064
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05934331-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20310806
DTEND;VALUE=DATE:20310807
SUMMARY:Toripalimab: Phase 2 readout est. (NCT05934331)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A LM-302 Combination With Other 
 Anti-Tumor Therapies Phase ll Study\nEstimated primary completion: 6 Augus
 t 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05934
 331
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154069-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07154069)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Adapt
 ive Immunotherapy for Nasopharyngeal Carcinoma\nEstimated primary completi
 on: September 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 oripalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07154069
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629817-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20320315
DTEND;VALUE=DATE:20320316
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07629817)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Surgery vs. Radical Chemoradioth
 erapy for Esophageal SCC After Neoadjuvant Immunochemotherapy\nEstimated p
 rimary completion: 15 March 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07629817
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540390-2018@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07540390)
DESCRIPTION:Toripalimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: GAPP 
 Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Ad
 vanced NPC.\nEstimated primary completion: 31 December 2032. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07540390
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
